alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 926–950 of 963 studies with an author at Harvard University (US) (page 38 of 39) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Molecular syndromology 2018-10-30

In the last decade, a number of important research advances in different fields have allowed Down syndrome (DS) research to flourish, creating a time of both unparalleled opportunity and considerable challenge. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Evidence-Based Mental Health 2012-06-22

Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder QUESTION Question: Is atypical antipsychotic use associated with incident diabetes or hyperlipidaemia in older people without schizophrenia or bipolar disorder? 1 key finding →

Participants: 75 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lecanemab, aducanumab, and donanemab bind the same human Alzheimer disease Aβ aggregates at different epitopes

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2025-12-01

Within the limitations of measuring in vitro equilibrium binding activity of in‐house recombinant antibodies to aqueously extracted Aβ from human postmortem brain tissue, we could not discern a population of Aβ aggregates ( e.g . protofibrils) accessible to one antibody but not the other two. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Functional connectivity differences in the default mode and frontoparietal networks in older adults with Down syndrome are related to obstructive sleep apnea

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2025-12-01

There was a significant interaction between OSA and diagnosis for within- and between-DMN FC (p-values<0.05). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Correlating antemortem amyloid PET burden, postmortem MRI volumes, with neuropathological measures: Insights from Down syndrome and Alzheimer's disease cohorts

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2025-12-01

The ABC-DS cohort showed similar Aβ PET burden but had a lower prevalence of ApoE4 carriers, younger age at clinical diagnosis and autopsy, shorter PET-autopsy interval, smaller amygdala and hippocampal volumes, more advanced CERAD scores, and no atherosclerosis compared to ADRC cohort (Figure 1). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D

✓ Peer-reviewed alzhub usefulness score 36 out of 100. JAMA Health Forum 2023-02-24

This cross-sectional study examines the characteristics of prior authorization policies for new drugs in Medicare Part D to understand whether they are consistent with US Food and Drug Administration indications. 1 key finding →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neurobiology of aging 2001-09-01

With high resolution, quantitative magnetic resonance imaging (MRI) techniques, it is now possible to examine alterations in brain anatomy in vivo and to identify regions affected in the earliest stages of Alzheimer's disease (AD). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Trends in hospital discharge outcomes among high-risk Medicare beneficiaries before and during the COVID-19 pandemic

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Health Affairs Scholar 2025-03-18

We found that COVID patients initially experienced substantially longer hospital stays (8.3 vs 4.6 days) and higher 30-day mortality (34% vs 5%) compared to patients without COVID. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Degree of Adherence to Brain Health Recommendations in Patients Pursuing Anti-Amyloid Antibody Therapy for Alzheimer’s Disease (S23.003)

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Neurology 2025-04-07

To determine the degree to which patients with early Alzheimer disease (AD) being evaluated for anti-amyloid antibody therapies (AATs) adhere to optimal brain-health/lifestyle recommendations. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Functional connectivity differences in the default mode and frontoparietal networks in older adults with Down syndrome are related to obstructive sleep apnea

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Alzheimer s & Dementia 2025-12-01

We observed higher within‐ and between‐DMN FC in the CS‐OSA compared to the CI‐OSA group; however, this difference was not observed between the CS‐nonOSA and CI‐nonOSA groups. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

On the association analysis of genome-sequencing data: A spatial clustering approach for partitioning the entire genome into nonoverlapping windows

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Genetic epidemiology 2017-03-21

For the association analysis of whole-genome sequencing (WGS) studies, we propose an efficient and fast spatial-clustering algorithm. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prevalence of Diagnosed Alzheimer’s Disease and Related Dementias in Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Innovation in Aging 2020-12-01

A third of Medicare beneficiaries are enrolled in Medicare Advantage (MA); however, little is known about MA beneficiaries diagnosed with Alzheimer’s disease and related dementias (AD/ADRD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Does Demographic Normalisation Improve the Accuracy of the MoCA and the MMSE for Detecting Mild Cognitive Impairment and Early Dementia ?

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer s & Dementia 2025-12-01

Surprisingly, demographic normalisation worsened rather than improved diagnostic accuracy for detecting MCI with both MoCA and MMSE, reducing their effectiveness as diagnostic tools and confirming our hypothesis. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Vascular Considerations for Patients Receiving Amyloid Immunotherapy

✓ Peer-reviewed alzhub usefulness score 29 out of 100. Innovation in Aging 2025-12-01

Amyloid-related imaging abnormalities (ARIA) in the form of edema/effusions (ARIA-E) or hemorrhagic lesions (ARIA-H) are the most impactful adverse event associated with anti-amyloid immunotherapy for Alzheimer disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A head-to-head comparison of multiple amyloid PET radiotracers for Down syndrome clinical trials

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-03-19

Adults with Down syndrome carry high risk of developing Alzheimer’s disease and efforts to include this population in clinical trials remain limited. 4 key findings →

Design: longitudinal study Participants: 237 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A disease similarity approach identifies short-lived Niemann-Pick type C disease mice with accelerated brain aging as a novel mouse model for Alzheimer’s disease and aging research

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2024-04-23

Since its first description in 1906 by Dr. Alois Alzheimer, Alzheimer’s disease (AD) has been the most common type of dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed